Search our Database of Scientific Publications and Authors

I’m looking for a

    6973 results match your criteria Thyroid Medullary Carcinoma

    1 OF 140

    Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.
    Oncol Lett 2017 Dec 26;14(6):6485-6496. Epub 2017 Sep 26.
    Division of Pathology Diagnostic Services, Cytology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
    Despite considerable advances in the understanding of thyroid gland biology, correctly diagnosing thyroid nodules and treating high-grade thyroid carcinoma remains challenging. Cancer/testis (CT) antigens have emerged as potential diagnostic tools as well as targets of potential cancer vaccinations. In the present study, a total of 117 patients who underwent surgical therapy for thyroid disease were available for analysis. Read More

    Next generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of Neurofibromatosis Type 1.
    Eur J Endocrinol 2017 Nov 20. Epub 2017 Nov 20.
    B Klink, Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
    Objective Our objective was to improve molecular diagnostics in patients with hereditary pheochromocytoma and paraganglioma (PPGL) by using next generation sequencing (NGS) multi-gene panel analysis. Derived from this study we here present three cases that were diagnosed with NF1 germline mutations but did not have a prior clinical diagnosis of Neurofibromatosis Type 1 (NF1). Design We performed genetic analysis of known tumor predisposition genes, including NF1, using a multi-gene NGS enrichment-based panel applied to a total of 1029 PPGL patients. Read More

    Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.
    World J Oncol 2014 Apr 6;5(2):81-89. Epub 2014 May 6.
    Division of Pathology, Overlook Medical Center, 99 Beauvoir Ave, Summit, NJ 07902, USA.
    Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, most patients are able to tolerate the recommended dose of 140 mg daily. Surgical resection is the primary treatment for medullary thyroid carcinoma. Read More

    Two-stage thyroidectomy in the era of intraoperative neuromonitoring.
    Gland Surg 2017 Oct;6(5):453-463
    Department of Endocrine Surgery, Central Clinic of Athens, Athens, Greece.
    Background: The use of intraoperative neuromonitoring (IONM) provides surgeons with real time information about recurrent laryngeal nerves (RLN) functional integrity. Hence, allowing them to modify the initially scheduled bilateral procedure, to a two-stage thyroidectomy in cases of loss of signal (LOS) on the first side of resection resulting in minimization of bilateral RLN injury. The purpose of our study was to present our results since the implementation of the above mentioned process in both malignant and benign thyroid disease. Read More

    Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: a novel model of invasive medullary thyroid carcinoma.
    Endocr Relat Cancer 2017 Nov 15. Epub 2017 Nov 15.
    N Pellegata, Institute for Diabetes and Cancer, Helmholtz Zentrum München, Neuherberg, Germany
    Rats affected by the MENX syndrome spontaneously develop multiple neuroendocrine tumors (NETs) including adrenal, pituitary and thyroid gland neoplasms. MENX was initially reported to be inherited as a recessive trait and affected rats were found to be homozygous for the predisposing Cdkn1b mutation encoding p27. We here report that heterozygous MENX mutant rats (p27+/mut) develop the same spectrum of NETs seen in the homozygous (p27mut/mut) animals but with slower progression. Read More

    Advances in the management of MEN2.
    Endocr Relat Cancer 2017 Nov 15. Epub 2017 Nov 15.
    S Wells, Genetics Branch, National Institutes of Health, Bethesda, 20892-0001, United States
    Medullary thyroid carcinoma (MTC), a tumor derived from the neural crest, occurs either sporadically or as the dominant component of the type 2 multiple endocrine neoplasia (MEN) syndromes, MEN2A and MEN2B. The discovery that mutations in the RET protooncogene cause hereditary MTC was of great importance, since it led to the development of novel methods of diagnosis and treatment. For example, the detection of a mutated RET allele in family members at risk for inheriting MEN2A or MEN2B signaled that they would develop MTC, and possibly other components of the syndromes. Read More

    Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience.
    World J Surg 2017 Nov 13. Epub 2017 Nov 13.
    Endocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
    Background: Medullary thyroid carcinoma (MTC) is a rare C cells-derived tumor, with a hardly predictable long-term prognosis. This study was aimed to evaluate the predictive factors of cure and survival after surgery for MTC in a monocentric series.

    Methods: A retrospective analysis of the long-term outcomes was assessed in 255 MTC patients operated between 1980 and 2015 at Padua University hospital. Read More

    Genetic and Epigenetic of Medullary Thyroid Cancer
    Iran Biomed J 2017 11 11. Epub 2017 Nov 11.
    Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
    Medullary thyroid carcinoma (MTC) is an infrequent, calcitonin producing neuroendocrine tumor and initiates from the parafollicular C cells of the thyroid gland. Several genetic and epigenetic alterations are collaterally responsible for medullary thyroid carcinogenesis. In this review article, we shed light on all the genetic and epigenetic hallmarks of MTC. Read More

    Metastatic medullary thyroid carcinoma or calcitonin-secreting carcinoid tumor of lung? A diagnostic dilemma in a patient with lung mass and thyroid nodule.
    Diagn Cytopathol 2017 Nov 10. Epub 2017 Nov 10.
    Professor of Pathology, University of Minnesota, Minneapolis 55455.
    Calcitonin-secreting neuroendocrine tumors are rare and have been reported in literature as case reports or case series in various organs including lung, pancreas, larynx, bladder, and ovary. These tumors have similar cytologic features and immunohistochemical profile to medullary thyroid carcinoma and thus it is difficult to distinguish them, especially when calcitonin-secreting neuroendocrine tumors are intermediate or higher grade and there is a mass lesion in the thyroid gland. Here, we report a rare case of calcitonin secreting atypical carcinoid tumor of the lung in a patient with thyroid nodule. Read More

    Patients with papillary thyroid carcinoma associated with high stimulated serum calcitonin levels.
    Endocrinol Diabetes Metab Case Rep 2017 3;2017. Epub 2017 Nov 3.
    Departments of Endocrinology.
    Among various substances produced by C-cells, the most important one is calcitonin (CT) that is used for detection, post-operative follow-up and evaluation of individuals at risk of developing medullary thyroid carcinoma (MTC). However, the role of serum CT measurement in the evaluation of thyroid nodules has been widely discussed, and there is still no consensus about the role of CT in the initial evaluation of all thyroid nodules. Two patients with thyroid nodules whose fine-needle aspiration results were compatible with benign cytology besides having mildly elevated basal serum calcitonin levels were reported. Read More

    CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.
    Br J Cancer 2017 Nov 7. Epub 2017 Nov 7.
    Department of Surgery (A), Heinrich-Heine-University and University Hospital Duesseldorf, Moorenstr. 5, Duesseldorf 40225, Germany.
    Background: Medullary thyroid carcinoma (MTC) is a rare and challenging endocrine malignancy. Once spread, the therapeutic options are limited and the outcome poor. For these patients, the identification of new druggable biological markers is of great importance. Read More

    MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
    Exp Mol Pathol 2017 Oct 26;103(2):229-236. Epub 2017 Oct 26.
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, United States. Electronic address:
    Background: Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are well-recognized post-transcriptional regulators of gene expression. This study examines the expression of microRNA-21 (miR-21) and lncRNA MALAT1 in medullary thyroid carcinomas (MTCs) and their effects on tumor behavior.

    Methods: Tissue microarrays (TMAs) were constructed using normal thyroid (n=39), primary tumors (N=39) and metastatic MTCs (N=18) from a total of 42 MTC cases diagnosed between 1987 and 2016. Read More

    Thyroid 2017 Nov 4. Epub 2017 Nov 4.
    The Ohio State University, Medicine/Endocrinology , 445D McCampbell Hall , 1581 Dodd Drive , Columbus, Ohio, United States , 43210 ;
    Background: The Retinoblastoma (RB) transcriptional corepressor 1 protein functions to slow cell cycle progression. Inactivation of RB by reduced expression and/or hyperphosphorylation allow for enhanced progression through cell cycle. Murine models develop medullary thyroid carcinoma (MTC) after generalized loss of RB; however, RB expression in MTC has been evaluated only in a small number of tumors with differing results. Read More

    High-resolution proteomics and metabolomics in thyroid cancer: Deciphering novel biomarkers.
    Crit Rev Clin Lab Sci 2017 Oct 30:1-12. Epub 2017 Oct 30.
    d Proteomic Unit , Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB-Arrixaca), Universidad de Murcia , Murcia , Spain.
    The incidence of thyroid cancer (TC) - the most common endocrine malignancy - has been increasing sharply since the mid-1990s. The rate of TC incidence in both men and women has been faster than any other cancer. Both improved diagnoses (i. Read More

    Aberrant expression of CD20 in thyroid cancer and its clinicopathologic significance.
    Hum Pathol 2017 Oct 24. Epub 2017 Oct 24.
    Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. Electronic address:
    CD20 is the first line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias. Recently, aberrant CD20 expression has been described in a small series of papillary thyroid carcinomas (PTC). We aimed to evaluate CD20 immunoexpression and to perform clinicopathologic correlation in a large set of thyroid tumors, including a cohort of high-grade thyroid cancer. Read More

    Patient quality of life and prognosis in MEN2.
    Endocr Relat Cancer 2017 Oct 24. Epub 2017 Oct 24.
    K Winter, Counselling, Association for Multiple Endocrine Neoplasia Disorders, Tunbridge Wells, United Kingdom of Great Britain and Northern Ireland.
    Multiple endocrine neoplasia type 2 (MEN2) refers to the autosomal dominant neuroendocrine tumour syndromes, MEN type 2A (MEN2A) and MEN type 2B (MEN2B). They are typified by the development of medullary thyroid carcinoma (MTC), phaeochromocytoma and parathyroid hyperplasia in MEN2A, and MTC, phaeochromocytomas, ganglioneuromatosis and skeletal abnormalities in MEN2B. The aggressiveness of MTC is variable according to genotype, and although it is still the major cause of mortality in both conditions, prognosis has improved dramatically in those diagnosed and treated at a young age thanks to predictive genetic testing. Read More

    Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.
    Ann Clin Lab Sci 2017 Sep;47(5):523-528
    School of Health Professions Program in Diagnostic Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Medullary thyroid carcinoma (MTC), an aggressive form of thyroid cancer, occurs sporadically in approximately 75% of MTCs. RET and RAS mutations play a role in about 40% and 15%, respectively, of sporadic MTCs and are predominant drivers in MTC pathways. These mutations are some of the most comprehensively described and screened for in MTC patients; however, in recent studies, other mutations in the CDKN2C gene (p18) have been implicated in the tumorigenesis of MTC. Read More

    Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas: Clinicopathological Study of 25 Cases and Review of the Literature.
    Endocr Pathol 2017 Dec;28(4):351-361
    Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
    Increased levels of circulating calcitonin are a clue in the diagnosis of medullary thyroid carcinoma. However, hypercalcitoninemia can also be related to other pathological conditions, including pancreatic neuroendocrine neoplasms (PanNENs). Ectopic hormonal production is not unusual in both functioning and non-functioning PanNENs; however, little is known about the frequency of calcitonin expression in these neoplasms. Read More

    [Dye-tattooing under ultrasound guidance in preoperative localization of neck recurrences from thyroid cancer].
    Zhonghua Zhong Liu Za Zhi 2017 Oct;39(10):764-767
    Department of Head and Neck Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China.
    Objective: To evaluate the efficacy and safety of the application of dye-tattooing under ultrasound guidance in preoperative localization of neck recurrences from thyroid cancer. Methods: Between October 2014 to September 2016, 25 patients with 34 lesions were enrolled. There were 22 cases of papillary thyroid carcinoma and three cases of medullary thyroid carcinoma, all of which could not be detected by computed tomography. Read More

    Dermal Hyperneury and Multiple Sclerotic Fibromas in Multiple Endocrine Neoplasia Type 2A Syndrome.
    JAMA Dermatol 2017 Oct 18. Epub 2017 Oct 18.
    Department of Dermatology, Fundación Jiménez Diaz, Universidad Autónoma, Madrid, Spain.
    Importance: Multiple endocrine neoplasia type 2 (MEN 2) syndrome is an autosomal dominant, hereditary cancer disorder caused by germline mutations in the RET (formerly MEN2A, MEN2B) proto-oncogene located on chromosomal band 10q11.21. Two distinct clinical forms have been described as the following phenotypes: multiple endocrine neoplasia type 2A (MEN 2A) and multiple endocrine neoplasia type 2B (MEN 2B) syndromes. Read More

    Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
    Ann Oncol 2017 Nov;28(11):2813-2819
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, USA.
    Background: Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement in progression-free survival with cabozantinib versus placebo in patients with progressive medullary thyroid cancer (MTC). Final analysis of overall survival (OS), a key secondary endpoint, was carried out after long-term follow-up.

    Patients And Methods: EXAM compared cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Read More

    Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma.
    Clin Case Rep 2017 Oct 24;5(10):1628-1633. Epub 2017 Aug 24.
    Division of Medical OncologyDepartment of MedicineFaculty of MedicineRamathibodi HospitalMahidol UniversityBangkokThailand.
    Systemic treatment of Medullary thyroid carcinoma (MTC) is currently limited to the use of a tyrosine kinase inhibitor. Cytotoxic chemotherapy is not routinely recommended in the earlier lines of treatment due to the lack of efficacy. We describe a patient with locally advanced MTC who had an uncommon response to cisplatin and etoposide. Read More

    Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman.
    Oman Med J 2017 Sep;32(5):365-370
    Department of Chemical Pathology, Directorate of Laboratory Medicine and Pathology, Royal Hospital, Muscat, Oman.
    Objectives: To evaluate the significance of serum chromogranin A (CgA) status in patients with and without different neuroendocrine tumors (NETs) by conducting a retrospective assessment of the diagnostic utility and limitations of CgA as a biomarker for NETs in a tertiary care hospital in Oman.

    Methods: We conducted a retrospective analysis of CgA requests referred to the Clinical Biochemistry Laboratory, Royal Hospital, Oman over a 24-month period (April 2012 to March 2014). During this time, 302 CgA tests for 270 patients (119 males and 151 females; age range 11-86 years and mean±standard deviation (SD) 44. Read More

    Detection of early stage medullary thyroid carcinoma by measuring serum calcitonin using an electro chemiluminescence immuno-assay: A case report of a young Japanese woman with a high-risk RET mutation.
    Clin Pediatr Endocrinol 2017 28;26(4):243-249. Epub 2017 Sep 28.
    Department of Pediatrics, Niigata City General Hospital, Niigata, Japan.
    Medullary thyroid carcinoma (MTC) in multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant disorder caused by the mutation of the RET proto-oncogene, that shows nearly complete penetration. The American Thyroid Association guidelines recommend prophylactic thyroidectomy for patients with high-risk RET mutations. However, in Japan, ethical and medical issues may preclude prophylactic treatment in young patients. Read More

    (18)F-fluorodeoxyglycose-avid thyroid incidentalomas: the importance of contextual interpretation.
    J Nucl Med 2017 Oct 12. Epub 2017 Oct 12.
    Peter MacCallum Cancer Centre, Australia.
    Background: FDG-avid thyroid incidentalomas (TI) are seen in approximately 2.5% of patients imaged for staging or response assessment of malignancy and represent thyroid cancer in approximately 35% of cases. Consequently, the 2015 ATA guidelines strongly recommend investigation of all FDG-avid nodules ≥1cm with US and fine needle aspiration cytology (FNA). Read More

    Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib.
    J Nucl Med 2017 Oct 12. Epub 2017 Oct 12.
    University Hospital Würzburg, Germany.
    Introduction: Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKI). We aimed to assess the role of metabolic imaging using 2-deoxy-2-((18)F)fluoro-D-glucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) shortly before and 3 months after initiation of TKI treatment. Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline (18)F-FDG PET/CT prior to and 3 months after TKI treatment initiation. Read More

    Sunitinib in the treatment of thyroid cancer.
    Curr Med Chem 2017 Oct 6. Epub 2017 Oct 6.
    Department of Clinical and Experimental Medicine, University of Pisa, Via Savi, 10, I-56126, Pisa. Italy.
    Background: Sunitinib (SU11248) is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor (TKI), that inhibits receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), c-KIT, fms-related tyrosine kinase 3 (FLT3) and RET. The concurrent inhibition of these pathways reduces tumor vascularization and causes cancer cell apoptosis, inducing a tumor shrinkage. Sunitinib is approved for the treatment of imatinib-resistant gastrointestinal stromal tumor (GIST), renal carcinoma, and pancreatic neuroendocrine tumors. Read More

    Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.
    Mol Diagn Ther 2017 Oct 6. Epub 2017 Oct 6.
    Cellular and Molecular Endocrine Research Center (CMERC), Research Institute for Endocrine Sciences of Shahid Beheshti University of Medical Sciences, 19395-4763, Tehran, Iran.
    Thyroid carcinoma (TC) is the most frequent malignant neoplasm of the endocrine system. Molecular methods for diagnosis of invasive thyroid disease can be effectively adopted. Epigenetic factors play an important role in the diversity patterns of gene expression and the phenotypic and biological characteristics of TC subtypes. Read More

    Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.
    Ann Nucl Med 2017 Oct 6. Epub 2017 Oct 6.
    San Raffaele G. Giglio Institute, Cefalù, PA, Italy.
    Introduction: Medullary thyroid carcinoma (MTC) is a malignancy accounting for about 5-8% of thyroid cancers. Serum calcitonin and carcinoembryonic antigen (CEA) levels are widely used to monitor disease progression. However, prognostic factors able to predict outcomes are highly desirable. Read More

    Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
    JAMA Surg 2017 Sep 27. Epub 2017 Sep 27.
    Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, UCLA David Geffen School of Medicine, University of California, Los Angeles.
    Importance: The association of initial neck dissection with recurrence in medullary thyroid carcinoma (MTC) has not been evaluated on a population level to date.

    Objective: To elucidate risk factors associated with reoperation in MTC and disease-specific mortality.

    Design, Setting, And Participants: A retrospective analysis was performed of hospital data obtained from the California Cancer Registry and the Office of Statewide Health Planning and Development from January 1, 1999, through December 31, 2012. Read More

    Patterns of Thyroid Cancers in Southeastern Nigeria: A 15 Year Histopathologic Review (2000-2014).
    J Clin Diagn Res 2017 Aug 1;11(8):EC16-EC19. Epub 2017 Aug 1.
    Senior Lecturer/Consultant, Department of Radiation Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria.
    Introduction: Thyroid Cancer (TC) continues to be the most common endocrine cancer with a worldwide increase in incidence over the last three decades. This trend has been reported in all continents except Africa, where detection is adjudged to be insufficient, making it imperative for us to re-evaluate the patterns in our environment.

    Aim: To determine the patterns of TCs in Southeastern Nigeria. Read More

    Axillary Lymph Node Metastasis in Medullary Thyroid Carcinoma: A Case Report.
    Iran J Otorhinolaryngol 2017 Sep;29(94):295-297
    Department of Cardiothoracic Surgery, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
    Introduction: Medullary thyroid cancer (MTC) is an uncommon neoplasm originating from parafollicular C cells. Distant metastasis in MTC, such as axillary node involvement, is extremely rare.

    Case Report: The present study describes a known case of MTC with axillary lymph node metastasis in a 31-year-old woman. Read More

    Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
    Pathol Int 2017 Nov 27;67(11):580-584. Epub 2017 Sep 27.
    Department of Pathology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611.
    We describe a 74-year-old man with a nodular goiter accompanied by an incidental sporadic minute medullary thyroid carcinoma (MTC). Histopathologically, the MTC was a well-defined 1.7 mm tumor in the upper one-third right lobe, with solid cell nests (SCNs) adjacent to the MTC. Read More

    Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma.
    Physiol Res 2017 Sep;66(Supplementum 3):S397-S408
    Institute of Endocrinology, Prague, Czech Republic.
    This work discusses the clinical performance of chromogranin A, free metanephrine and normetanephrine determination in plasma using a radioimmunoanalytical methods for the diagnosis of pheochromocytoma and paraganglioma. Blood samples were collected from 55 patients (46 pheochromocytomas, 9 paragangliomas). A sampling of biological materials was performed preoperatively and about one week, six months and one year after adrenal gland surgery. Read More

    Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.
    Endocrine 2017 Dec 25;58(3):474-480. Epub 2017 Sep 25.
    Endocrinology Department, Instituto Nacional do Cancer do Rio de Janeiro, Praça da Cruz Vermelha 23, 8th floor, Centro, Rio de Janeiro, RJ, 20230-130, Brazil.
    Purpose: Medullary thyroid carcinoma (MTC) is a malignant neoplasm of parafollicular cells. Because it is a neuroendocrine tumor, it has known somatostatin receptors (SSTRs). The actual frequencies of the SSTR subtypes and their potential influences (by binding with endogenous somatostatin) on MTC cell proliferation have not been fully elucidated to date. Read More

    Metastatic neuroendocrine tumor of the esophagus with features of medullary thyroid carcinoma.
    Intractable Rare Dis Res 2017 Aug;6(3):224-229
    Pathology and Laboratory Medicine Service, James A. Haley VA Hospital, Tampa, FL, USA.
    A 41-year-old female presented with a pedunculated mass in the upper esophagus and bilateral lymphadenopathy. Biopsies suggested a neuroendocrine tumor, possibly carcinoid, and ensuing imaging revealed cervical lymph node metastases. The esophageal mass was removed endoscopically and discovered by pathologists to closely resemble medullary thyroid carcinoma (MTC) on immunohistochemistry staining. Read More

    A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11.
    Oncol Lett 2017 Sep 15;14(3):3552-3558. Epub 2017 Jul 15.
    MyGenostics, Inc., Beijing 101318, P.R. China.
    The present study identified the clinical features of the largest multiple endocrine neoplasia type 2 (MEN2) A pedigree from China, with a novel double missense rearranged during transfection (RET) mutation (C634Y/D707E). To the best of our knowledge, the D707E mutation has not been identified to date. In the present study, a total of 101 family members who originated from a large pedigree (134 members in total) underwent RET mutation screening by next-generation sequencing and polymerase chain reaction (PCR) amplification, followed by direct bidirectional DNA sequencing. Read More

    The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population.
    Oncotarget 2017 Aug 6;8(35):58304-58308. Epub 2017 Apr 6.
    Oncology Clinic, Holycross Cancer Centre, Kielce, Poland.
    Thyroid cancer is one of the most frequently diagnosed cancers of the endocrine system. There are no known genetic risk factors for non-medullary thyroid cancer, other than a small number of hereditary syndromes; however, approximately 5% of non-medullary thyroid cancer, designated familial non-medullary thyroid cancer, exhibits heritability. The p. Read More

    A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy.
    Thyroid Res 2017 19;10. Epub 2017 Sep 19.
    Medical Oncology, British Columbia Cancer Agency, 600 W 10th Avenue, Vancouver, BC V5Z 4E6 Canada.
    Background: Medullary thyroid carcinoma (MTC) accounts for 1-2% of all thyroid cancers. The clinical course of metastatic disease can be indolent. Our aim was to characterize the natural history of disease to evaluate the true proportion of patients who would be eligible for the currently available systemic therapies. Read More

    Calcitonin receptor expression in medullary thyroid carcinoma.
    PeerJ 2017 13;5:e3778. Epub 2017 Sep 13.
    Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.
    Background: Calcitonin expression is a well-established marker for medullary thyroid carcinoma (MTC); yet the role of calcitonin receptor (CTR), its seven-transmembrane G-protein coupled receptor, remains to be established in C-cells derived thyroid tumors. The aim of this work was to investigate CTR expression in MTC and to correlate such expression with clinicopathological features in order to evaluate its possible role as a prognostic indicator of disease aggressiveness and outcome.

    Methods: Calcitonin receptor expression was analyzed in a series of 75 MTCs by immunohistochemistry, and by qPCR mRNA quantification in specimens from four patients. Read More

    Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
    Thyroid 2017 Nov 24;27(11):1450-1455. Epub 2017 Oct 24.
    Department of Medical Oncology, Hospital General de Ciudad Real , Ciudad Real, Spain .
    Background: Medullary thyroid carcinoma (MTC) is a rare disease. Treatment options for recurrent disease are limited. Although somatostatin analogues might have a role as anticancer agents in MTC, the evidence is inconclusive. Read More

    Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation.
    Stem Cell Res 2017 Aug 22;23:154-157. Epub 2017 Jul 22.
    INSERM U935, Université Paris Sud, 94800, Villejuif, France; ESTeam Paris Sud, INSERM U935, Université Paris Sud, Université Paris-Saclay, 94800, Villejuif, France; INGESTEM National IPSC Infrastructure, 94800 Villejuif, France; Division of Hematology, Paris Sud University Hospitals, Le Kremlin Bicêtre 94275, France; Division of Hematology, Paris Sud University Hospitals, Villejuif 94800, France. Electronic address:
    Multiple Endocrine Neoplasia Type 2B (MEN2B) is a cancer-predisposing syndrome that affects patients with germline RET mutations. The clinical spectrum of the syndrome includes medullary thyroid carcinoma (MTC) and pheochromocytoma. Currently, there is no satisfactory model recapitulating all the features of the disease especially at the level of stem cells. Read More

    One-step synthesis of [(18) F]cabozantinib for use in positron emission tomography imaging of c-Met.
    J Labelled Comp Radiopharm 2017 Sep 18. Epub 2017 Sep 18.
    Norwegian Medical Cyclotron Center, Research&Development, Oslo, Norway.
    Cabozantinib is an FDA approved kinase inhibitor for the treatment of medullary thyroid cancer and advanced renal cell carcinoma, which exerts its therapeutic effect by inhibiting, among others, the tyrosine kinase c-Met. Non-invasive imaging techniques are becoming increasingly important clinically to ensure drug efficacy, staging, monitoring and patient stratification. PET isotope labelled tyrosine kinase inhibitors have, for the same reason, potential as PET tracers for imaging of various cancers. Read More

    Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
    Best Pract Res Clin Endocrinol Metab 2017 Jun 10;31(3):349-361. Epub 2017 May 10.
    Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address:
    Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC. Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials. The toxicity burden associated to TKIs is not negligible. Read More

    1 OF 140